1. Home
  2. MDWD vs SMID Comparison

MDWD vs SMID Comparison

Compare MDWD & SMID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • SMID
  • Stock Information
  • Founded
  • MDWD 2000
  • SMID 1960
  • Country
  • MDWD Israel
  • SMID United States
  • Employees
  • MDWD N/A
  • SMID 232
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • SMID Building Materials
  • Sector
  • MDWD Health Care
  • SMID Industrials
  • Exchange
  • MDWD Nasdaq
  • SMID Nasdaq
  • Market Cap
  • MDWD 179.1M
  • SMID 163.4M
  • IPO Year
  • MDWD 2014
  • SMID 1995
  • Fundamental
  • Price
  • MDWD $16.78
  • SMID $30.54
  • Analyst Decision
  • MDWD Strong Buy
  • SMID
  • Analyst Count
  • MDWD 1
  • SMID 0
  • Target Price
  • MDWD $28.00
  • SMID N/A
  • AVG Volume (30 Days)
  • MDWD 64.7K
  • SMID 32.7K
  • Earning Date
  • MDWD 08-14-2024
  • SMID 08-14-2024
  • Dividend Yield
  • MDWD N/A
  • SMID N/A
  • EPS Growth
  • MDWD N/A
  • SMID N/A
  • EPS
  • MDWD N/A
  • SMID 0.87
  • Revenue
  • MDWD $20,141,000.00
  • SMID $68,434,000.00
  • Revenue This Year
  • MDWD $30.16
  • SMID N/A
  • Revenue Next Year
  • MDWD $18.44
  • SMID N/A
  • P/E Ratio
  • MDWD N/A
  • SMID $35.20
  • Revenue Growth
  • MDWD N/A
  • SMID 26.77
  • 52 Week Low
  • MDWD $7.26
  • SMID $17.10
  • 52 Week High
  • MDWD $24.00
  • SMID $48.87
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 41.90
  • SMID 48.56
  • Support Level
  • MDWD $16.25
  • SMID $28.74
  • Resistance Level
  • MDWD $17.48
  • SMID $32.00
  • Average True Range (ATR)
  • MDWD 0.97
  • SMID 2.49
  • MACD
  • MDWD -0.23
  • SMID -0.37
  • Stochastic Oscillator
  • MDWD 13.02
  • SMID 36.36

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

Share on Social Networks: